Molecular imprint polymer for urine biomarker isolation

早期发现癌症可以挽救生命。该项目涉及一种癌症患者筛查技术， 使用尿液中外源性代谢物的定量的非常早期阶段。BioMark Technologies Inc. 开发这项技术的基础上，增加了增加乙酰化的外源性 化合物金刚烷胺到乙酰金刚烷胺（AcAm）与酶的上调强烈相关 精胺/亚精胺N-乙酰转移酶（SSAT 1），与几种类型的癌症相关。的 目前可用的用于定量AcAm的分析方法是费力且昂贵的， 由于污染，直接使用拉曼光谱法降低成本已被证明是困难的 探针上的基质物质在本项目中，我们提出使用分子印迹聚合物（MIP）清洁 增加样品并富集目标分析物AcAm，使得分析所需的时间和成本都降低。 定量分析可以显着减少，使该技术在所有临床实验室中都可以使用。 开发的技术可以很容易地转移到BioMark Technologies Inc.，并将直接 对加拿大经济和加拿大人的健康和福祉都有好处。

Early detection of cancer saves lives. This project is related to a patients screening technology for cancers at very early stages using the quantification of an exogenous metabolite in urine. BioMark Technologies Inc. developed this technology based on the fact that increased the increased acetylation of an exogenous compound amantadine to acetylamantadine (AcAm) is strongly correlated to the up-regulation of the enzyme spermine/spermidine N-acetyltransferase (SSAT1), which is correlated to several types of cancers. The currently available analytical methods for the quantification of AcAm are laborious and costly, and efforts to reduce the cost with the direct use of Raman spectrometry have proven difficult because of the contamination of matrix material on the probes. In this project we propose to use molecular imprint polymer (MIP) to clean up the sample and enrich the target analyte AcAm, so that both the time and the cost required for the quantitative analysis can be significantly reduced to make this technology readily available in all clinical labs. The developed technology can be readily transferred to BioMark Technologies Inc., and will be of direct benefit to the Canadian economy and the health and well-being of Canadians.